A stem‐like autoimmune CD8 T cell population drives type 1 diabetes
Gearty SV, Dündar F, Zumbo P, Espinosa‐Carrasco G, Shakiba M, Sanchez‐Rivera F, Socci ND, Trivedi D, Lowe SW, Lauer P, Mohibullah N, DiLorenzo TP, Viale A, Betel D, Schietinger A. Nature 2022 Feb;602(7895):156‐161.
TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion
Shakiba M, Zumbo P, Dündar F, Espinosa‐Carrasco G, Camara S, Sanchez‐Rivera FG, Lowe SW, Koche RP, Reuter VP, Socci ND, Whitlock B, Tamzalit F, Huse M, Betel D, Philip M, Schietinger A. Journal of Experimental Medicine 2022 Feb 7;219(2):e20201966.
CD8 T cell differentiation and dysfunction in cancer
Philip M and Schietinger A. Nature Reviews Immunology. 2022 Apr;22(4):209‐223.
TOX is a critical regulator of tumour-specific T cell differentiation
Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P, Menocal L, Appleby H1, Camara S, Zamarin D, Walther T, Snyder A, Femia MR, Comen EA, Wen HY, Hellmann MD, Anandasabapathy N, Liu Y, Altorki NK, Lauer P, Levy O, Glickman MS, Kaye J, Betel D, Philip M, Schietinger A. Nature 2019 Jul;571(7764):270-274.
Chromatin states define tumour-specific T cell dysfunction and reprogramming.
Philip M, Fairchild L, Sun L, Horste E, Camara S, Shakiba M, Scott A, Lauer P, Viale A, Merghoub T, Hellmann M, Wolchok J, Leslie C, Schietinger A. Nature 2017 May 25;545(7655):452-456.
Featured in:
https://www.mskcc.org/blog/why-immune-cells-sometimes-fail-fight-cancer-and-what-do-about-it
http://cancerdiscovery.aacrjournals.org/content/early/2017/05/26/2159-8290.CD-RW2017-099
https://www.bioserendipity.com/2017/05/24/understanding-immune-checkpoint-pathways-to-improve-patient-response/
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.
Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, Schell TD, Garbi N, Greenberg PD. Immunity. 2016 Aug 8. 10.1016/j.immuni.2016.07.011
Tolerance and exhaustion: defining mechanisms of T cell dysfunction
Schietinger A, Greenberg PD. Trends Immunol. 2014 Feb;35(2):51-60. PMID: 24210163
Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state
Schietinger A, Delrow JJ, Basom RS, Blattman JN, Greenberg PD. Science. 2012 Feb 10;335(6069):723-7. PMID: 22267581
Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer
Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, Bindokas V, Bartkowiak T, Lee D, Herrmann A, Piston DW, Pittet MJ, Lin PC, Zal T, Schreiber H. Oncoimmunology. 2013 Nov 1;2(11):e26677. Epub 2013 Nov 4. PMID: 24482750
Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase
Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H. Journal of Experimental Medicine. 2010 Oct 25;207(11):2469-77. PMID: 20921286
A mutant chaperone converts a wild-type protein into a tumor-specific antigen
Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, Schreiber H. Science. 2006 Oct 13;314(5797):304-8. PMID: 17038624
IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner
Liu RB, Engels B, Schreiber K, Ciszewski C, Schietinger A, Schreiber H, Jabri B. Proc Natl Acad Sci U S A. 2013 May 14;110(20):8158-63. PMID: 23637340
Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer
Chou CK, Schietinger A, Liggitt HD, Tan X, Funk S, Freeman GJ, Ratliff TL, Greenberg NM, Greenberg PD. Journal of Immunology. 2012 Oct 15;189(8):3936-46. PMID: 22984076
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).
Stone JD, Aggen DH, Schietinger A, Schreiber H, Kranz DM. Oncoimmunology. 2012 Sep 1;1(6):863-873. PMID: 23162754
Densely granulated murine NK cells eradicate large solid tumors
Liu RB, Engels B, Arina A, Schreiber K, Hyjek E, Schietinger A, Binder DC, Butz E, Krausz T, Rowley DA, Jabri B, Schreiber H. Cancer Research. 2012 Apr 15;72(8):1964-74. PMID: 22374983
Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells
Philip M, Schietinger A, Schreiber H. Immunology. 2010 Aug;130(4):494-503. PMID: 20331471
Antibody recognition of a unique tumor-specific glycopeptide antigen
Brooks CL, Schietinger A, Borisova SN, Kufer P, Okon M, Hirama T, Mackenzie CR, Wang LX, Schreiber H, Evans SV. Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10056-61. PMID: 20479270
Specificity in cancer immunotherapy
Schietinger A, Philip M, Schreiber H. Seminars in Immunology. 2008 Oct;20(5):276-85. PMID: 18684640
Equilibrium between host and cancer caused by effector T cells killing tumor stroma
Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, Rowley DA, Schreiber H. Cancer Research. 2008 Mar 1;68(5):1563-71. PMID: 18316622
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells
Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, Kranz DM, Schreiber H. Journal of Experimental Medicine. 2007 Jan 22;204(1):49-55. PMID: 17210731
Priming of naive T cells inside tumors leads to eradication of established tumors
Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu YX. Nature Immunology. 2004 Feb;5(2):141-9. PMID: 14704792